Loading view.
Latest Past Events
IS02: Breakthrough Innovation: The First and Only Bispecific T-cell Engager (BiTE®) Therapy for 2L+ Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Room 33ABC, San Diego Convention Center
Presented by Amgen
Featured
IS01: Join us to hear thought leaders discuss a newly approved combination therapy that includes RYBREVANT® (amivantamab-vmjw)
Room 20BC, San Diego Convention Center
Presented by Johnson & Johnson
IS04: A Treatment Option for Certain Patients With Resectable Non-Small Cell Lung Cancer (NSCLC)
Room 20D, San Diego Convention Center
Presented by Merck & Co., Inc.